Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance.
about
The Elastin Receptor Complex: A Unique Matricellular Receptor with High Anti-tumoral PotentialNeuraminidase-1: a novel therapeutic target in multistage tumorigenesisSialylation regulates myofibroblast differentiation of human skin fibroblasts.Sialylation facilitates self-assembly of 3D multicellular prostaspheres by using cyclo-RGDfK(TPP) peptide.Oseltamivir phosphate monotherapy ablates tumor neovascularization, growth, and metastasis in mouse model of human triple-negative breast adenocarcinomaA miRNA signature of chemoresistant mesenchymal phenotype identifies novel molecular targets associated with advanced pancreatic cancer.Anti-influenza neuraminidase inhibitor oseltamivir phosphate induces canine mammary cancer cell aggressiveness.Transcriptional factor snail controls tumor neovascularization, growth and metastasis in mouse model of human ovarian carcinoma.Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.Therapeutic designed poly (lactic-co-glycolic acid) cylindrical oseltamivir phosphate-loaded implants impede tumor neovascularization, growth and metastasis in mouse model of human pancreatic carcinoma.α2,6-linked sialic acid serves as a high-affinity receptor for cancer oncolytic virotherapy with Newcastle disease virus.Sialylation transmogrifies human breast and pancreatic cancer cells into 3D multicellular tumor spheroids using cyclic RGD-peptide induced self-assembly.Identification of cancer genes that are independent of dominant proliferation and lineage programs.Oseltamivir phosphate released from injectable Pickering emulsions over an extended term disables human pancreatic cancer cell survival.Recent advances in "smart" delivery systems for extended drug release in cancer therapy
P2860
Q26765998-A2BDBE31-4DF7-4B12-B3B8-E179A164B8E2Q28066130-C5ED383E-524B-4E47-AF79-90773C450F9FQ33576339-813B94BF-D23C-431C-9751-F5762ABDA173Q33650423-841EB08E-D821-404E-8590-64E8550A00D2Q34700909-1A6CF6AF-2A3B-43E5-8472-F9640490AAC6Q35237480-8BC9CFD5-5A3F-4B95-8841-2037F6176E54Q35303234-27330D05-2800-4AD1-864D-10C5BFECEFDFQ36944505-CC3B13FC-E62C-4318-A825-57262D91AF26Q38694772-09A5B7C0-33CA-4509-BBA7-47A12FBC44EBQ38840619-0BC9E03A-7C3D-4A8F-9152-FC5B9757E7EBQ40131235-9005215C-0A57-4A69-89A5-72EA89C9E754Q41960794-D2B25816-57AF-45B4-A913-6A08881ACF2EQ47327357-FD432C55-D3F3-495B-B383-45CE73F3E256Q55248220-DFD3B1A7-9950-4A3A-B0B4-4D0426D15A01Q58735813-A0A01AC6-ECF3-44F6-8D99-551D808C891C
P2860
Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Therapeutic targeting of Neu1 ...... with acquired chemoresistance.
@en
type
label
Therapeutic targeting of Neu1 ...... with acquired chemoresistance.
@en
prefLabel
Therapeutic targeting of Neu1 ...... with acquired chemoresistance.
@en
P2093
P2860
P356
P1476
Therapeutic targeting of Neu1 ...... with acquired chemoresistance.
@en
P2093
Leah K O'Shea
Myron R Szewczuk
Ronald J Neufeld
Samar Abdulkhalek
Stephanie Allison
P2860
P304
P356
10.2147/OTT.S55344
P407
P577
2014-01-16T00:00:00Z